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Summary
Background: Haemophilus influenzae type b (Hib) conjugate vaccine reduces the risk of pneu-
monia in infants.
Objective: To determine the effect of Hib conjugate vaccine (HibCV) on the prevention of
pneumonia as a complication among infants hospitalized for bronchiolitis.
Methods: This record-based case—control study was conducted at The Children’s Hospital ‘‘Dr.
Ovidio Aliaga U’’ in La Paz, Bolivia during 2003 and 2004. Cases were infants hospitalized for
bronchiolitis under 1 year of age who developed radiological pneumonia during hospitalization.
Controls were patients who had good clinical progress without the use of antibiotics. Pneumonia
was defined by alveolar consolidation on chest X-ray that justified the use of antibiotics.
Results: Eighty patients were studied (16 cases and 64 controls). Their median age was 4.5
months. Demographic and clinical features were similar in both groups, except for a higher
proportion of vomiting (56.3% vs. 28.1%; p < 0.05) in the case group. The percentage of
unvaccinated infants was significantly higher in cases (68.8% vs. 26.6%; p < 0.05) and the length
of hospital stay longer (8.5  5.4 vs. 3.1  2.2 days; p < 0.05). There was a strong association
between unvaccinated infants and the occurrence of pneumonia as a complication (odds ratio
6.1, 95% confidence interval 1.8—20.1; p < 0.01).
Conclusions: Unvaccinated infants admitted for bronchiolitis have a higher risk of radiologically
confirmed pneumonia. Larger studies are needed to validate these results and reconsider the
burden of Hib infection among infants in less developed countries.
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Pneumonia is the leading killer of children and infants world-
wide.1 Haemophilus influenzae type b (Hib) is an important
cause of pneumonia in children, responsible for approxi-
mately 20—25% of severe pneumonia cases.1,2 Hib infection
is rare before 4 months of age, owing to passive protection by
transplacentally acquired antibodies, and again after 4 years
of age, by which time natural immunity has developed.3
Bronchiolitis is the most common lower respiratory infec-
tion in infants under 1 year and is usually caused by a viral
agent, predominantly respiratory syncytial virus (RSV).4 Sev-
eral recent studies in the USA, where Hib vaccination rates
are high, have reported low rates of serious bacterial infec-
tions including pneumonia in non-severe cases of bronchio-
litis and/or RSV infections (0—3.7%).4—6 However, no similar
data are available in the medical literature from developing
countries. This is likely because Hib is often underappre-
ciated as a cause of severe bacterial pneumonia due to the
lack of adequate testing facilities and resources for labora-
tory diagnosis. Consequently, the true burden of Hib disease
is not known.7,8 In Bolivia, 79% of infants under 1 year of age
were immunized against Hib in 2003,9 but data on nasophar-
yngeal Hib carriage in this population were not collected.
Case—control studies and vaccine trials have provided
evidence of the effectiveness of Hib conjugate vaccine
(HibCV) for the prevention of pneumonia and have helped
to estimate the burden of bacterial pneumonia.10 Hib vacci-
nation has been shown to reduce the risk of radiologically
confirmed pneumonia in community-based studies.10 How-
ever, no previous studies have reported benefits in infants
hospitalized for bronchiolitis. The objective of this study was
to determine the effect of HibCV for preventing pneumonia in
infants under 12 months of age hospitalized for bronchiolitis.
Methods
This case—control study included infants aged 2—11 months
admitted to the Respiratory Medicine Unit of The Children’s
Hospital ‘‘Dr. Ovidio Aliaga U’’ in La Paz, Bolivia for bronch-
iolitis during 2003 and 2004. Cases were infants under 1 year
of age who developed radiographically confirmed pneumonia
during hospitalization and required the use of antibiotics.
Controls were patients who had good clinical progress during
hospitalization without the use of antibiotics. Infants were
immunized using a diphtheria—tetanus—pertussis—hepatitis
B/Haemophilus influenzae type b (DTPw—HB/Hib) combina-
tion vaccine (Tritanrix1 HB + Hiberix1, GlaxoSmithKline) at
2, 4, and 6 months of age in accordance with the national
immunization schedule. Patients who received this vaccine
according to their age were classified as vaccinated infants
independently of the number of doses. None of the selected
infants had received the pneumococcal polysaccharide vac-
cine (PPV). Clinical diagnosis of bronchiolitis was established
by general pediatricians and senior pediatric residents who
admitted the patients through the Emergency Department
based on history and physical examination. All admitted
patients had World Health Organization (WHO) criteria for
severe respiratory infection based mainly on respiratory
rate.11 A chest radiograph was performed in all patients
on admission, which was used as evidence that thepatient did not have pneumonia at admission. Pneumonia
as a complication during hospitalization was defined radio-
graphically by an alveolar consolidation (a dense or fluffy
opacity that occupies a portion or whole of a lobe or of the
entire lung that may ormay not contain air-bronchograms) on
chest X-ray interpreted by attending physicians following
standardized parameters12 and that justified the use of
antibiotics. The need for a second chest radiograph and
the use of antibiotics during hospitalization was exclusively
based on the physician’s assessment and the patient’s clinical
progress. Vaccination status did not influence clinical deci-
sions because physicians were unaware of the hypothesis
under evaluation. All data collection was retrospective,
and every patient’s record was completely reviewed from
admission to discharge through the use of a structured form.
Information on clinical findings, laboratory results, interven-
tions, and outcomes was registered and transferred into a
database for statistical analysis.
The sample size was calculated considering a 21%
expected frequency of unvaccinated infants in the control
group,8 a risk six times greater among unvaccinated infants
than vaccinated infants for developing pneumonia, and sta-
tistical power of 80%, confidence level of 95%, and 4:1 ratio
between control/case groups. Descriptive statistics (mean,
median, standard deviation, and percent) were used to
describe study variables. Continuous variables were com-
pared using both the t-test and Mann—Whitney test for
normal and skewed distributions, respectively. Proportions
were compared by Chi-square statistics. The risk was esti-
mated by odds ratio (OR) and confidence intervals (CI) using
contingency tables. Finally, to assess the independent effect
of immunization status on the risk of radiological pneumonia,
we performed a multiple logistic regression analysis with
radiographic pneumonia as the outcome variable and statis-
tically significant differences found as predictor variables. All
data were analyzed with SPSS 12.0 for Windows (SPSS Inc.,
Chicago, IL, USA).
Results
The study sample consisted of 80 infants (64 controls and 16
cases) aged <1 year who were hospitalized for bronchiolitis
as a principal diagnosis over a 24-month period. Clinical and
demographic characteristics of these patients are shown in
Table 1. The median age of admitted patients was 4.5
months. The time of illness before admission was significantly
longer among infants who developed pneumonia as a com-
plication (6.8  5.0 vs. 4.4  3.5 days; p < 0.05). Vomiting as
a symptom occurred more frequently among cases than
controls (56.3% vs. 28.1%; p < 0.05). The proportion of exclu-
sively breastfed infants was similar in both groups. The white
blood cell (WBC) count was slightly increased in cases
(11.5  3.8 vs. 8.4  3.1  109/l ; p < 0.05), and the relative
lymphocyte count lower compared to controls.
The proportion of unvaccinated infants was significantly
higher in cases than in controls (68.8% vs. 26.6%; p < 0.05).
There was a strong association between not having received
HibCV and the occurrence of pneumonia in infants with
bronchiolitis (OR 6.1, 95% CI 1.8—20.1; p < 0.01). In the
multiple logistic regression analysis including immunization
status, time of illness before admission >96 h, and WBC
count >15  109/l, the adjusted OR (AOR) for estimating
Table 1 Clinical and sociodemographic characteristics of infants admitted for bronchiolitis
Cases (N = 16) Controls (N = 64) p-Value
Age (months) a 5.7  3.2 5.0  2.5 0.58
Gender, female/male (%) 31.2/68.8 56.3/43.7 0.07
Exclusively breastfed infants (%) 50 62.5 0.36
History of prematurity (<38 weeks) (%) 6.3 9.4 0.59
Unvaccinated infants (%) 68.8 26.6 <0.05
Clinical features
Time of illness before admission (days) a 6.8  5.0 4.4  3.5 <0.05
Cough (%) 87.5 96.9 0.12
Wheezing (%) 50.0 73.4 0.07
Increased work of breathing (%) 68.8 45.3 0.09
Crackles (%) 31.3 14.1 0.11
Fever at admission (%) 31.3 18.8 0.27
Vomiting (%) 56.3 28.1 <0.05
Lab tests
White blood cell count ( 109/l) a 11.5  3.8 8.4  3.1 <0.05
Relative lymphocyte count (%)a 46.7  11.7 58.1  16.5 <0.05
Progress
Length of hospital stay (days) a 8.5  5.4 3.1  2.2 <0.05
a Values expressed as mean  standard deviation.
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radiological pneumonia was 5.88 (95% CI 1.59—21.64;
p < 0.05).
Efforts to identify viral etiology through indirect fluores-
cent antibody detection of nasopharyngeal aspirates were
made in 23 patients. Viral testing was positive for RSV in nine
infants (39%). Two of these infants who had confirmed RSV
infection developed radiologically confirmed pneumonia and
required antimicrobial therapy. Blood cultures were not
performed in any case.
Discussion
In this case—control study that includes a sample of infants
hospitalized for bronchiolitis, the higher prevalence of radi-
ologically confirmed pneumonia found in unvaccinated
infants suggests that Hib infection could have a significant
role in bronchiolitis complications. To our knowledge, this is
the first study in the medical literature that reports the risk
of pneumonia in bronchiolitis considering vaccination status.
With the availability of effective vaccines against one of
the two leading bacterial pathogens causing childhood pneu-
monia in developing countries, the need for standardized
methods to collect data on the pneumonia disease burden
and the proportion of the burden preventable by vaccines has
become critical.13 Frustration associated with the lack of
refined clinical and laboratory diagnostic tools to define the
burden of vaccine-preventable diseases has prompted inves-
tigators to use vaccines as a ‘probe’.14 Previous studies in
developing countries support the concept that vaccines can
be used as ‘probes’ to unmask the burden of diseases that
may be missed by culture-based methods.9 Thus, vaccine
trials have helped to estimate the burden of vaccine-pre-
ventable disease by providing a measurable ‘vaccine effect’,
which is the difference in incidence or prevalence of a
condition between vaccinated and unvaccinated groups.10,15Although the present retrospective case—control study has
several well-known limitations,14 it is based on the ‘vaccine
trial’ concept described above.
The Hib vaccine is safe and effective in preventing inva-
sive Hib disease. In a recent Cochrane systematic review, the
findings of randomized controlled trials that evaluated the
effect of conjugate vaccines for preventing H. influenzae
type b infections suggest a reduction between 46% and 93% in
Hib invasive disease. Furthermore, authors found no evi-
dence that the effectiveness of the vaccine was modified
by the type of conjugate vaccine, the number of doses given
(two, three, or four), or age at first vaccination (2 months, 42
to 90 days, 3 months).2 In this study we did not specifically
evaluate these variables, but it is evident that even one dose
could be beneficial for preventing pneumonia in infants
hospitalized for bronchiolitis.
Classically, conventional diagnosis of pneumonia consists
of two stages: first, determining the syndrome by history,
clinical examination, and chest radiography; and second,
determining the etiology by microbiological, serological,
and molecular tests.16 In this study, the use of a radiographic
definition of pneumonia deserves particular consideration.
First, in contrast to the situation in industrialized countries,
the majority of Hib disease in developing countries manifests
as pneumonia. Unfortunately, it is more difficult to establish
a causative agent for pneumonia than for meningitis.9 To
identify a case of Hib pneumonia with certainty, it is neces-
sary to identify the Hib organism from culturing blood, lung
aspirate, or pleural fluid.15 Although blood culture offers an
excellent opportunity for the etiological diagnosis of bacter-
ial pneumonia, it is only useful in bacteremic pneumonia. The
yield from blood culture in patients with pneumonia has
ranged from 10% to 30%.14 A diagnostic lung tap may provide
valuable information for the etiology of non-bacteremic
pneumonia, but does not provide complete data.14
Second, the diagnosis of bacterial pneumonia in the face
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pulmonary infiltrates, positive tracheal aspirate cultures,
and elevated peripheral WBC counts are common findings
in respiratory infection and cannot be used to distinguish
bacterial from viral causation.17 To be effective in the devel-
oping world, a diagnostic test must be rapid, simple to
execute, and inexpensive and one has not yet been devel-
oped.16
Radiological findings are commonly accepted as the gold
standard for defining pneumonia.14 The presence of signifi-
cant alveolar consolidation is considered by most authorities
to be the most specific radiographic predictor of bacterial
pneumonia.12,13 In addition, previous studies had shown that
there is reasonable inter-observer agreement on the pre-
sence of alveolar consolidation.18,19 Although current evi-
dence does not support routine radiography in children with
bronchiolitis, this resource may be useful when the hospita-
lized infant does not improve at the expected rate, if the
severity of disease requires further evaluation, or if another
diagnosis is suspected.4 It has been suggested that bacterial
pneumonia in infants with bronchiolitis without consolidation
is unusual.20
The lack of confirmatory laboratory test results to diag-
nose bronchiolitis is also a limitation in this study. However,
the clinical utility of diagnostic testing in infants with sus-
pected bronchiolitis is not well supported by evidence.21 In
addition, recent American Academy of Pediatrics recommen-
dations for the diagnosis and management of bronchiolitis
suggest that bronchiolitis diagnosis should be based on
patient history and physical examination.4 Recent clinical
reviews on bronchiolitis confirm that infants younger than 6
months of age are at the highest risk of clinically significant
disease and that more than half of affected children are aged
between 2 and 7 months.22 This description correlates with
the demographic characteristics of infants studied in this
report. Additionally, cough and wheezing associated with
increased work of breathing, the most common clinical
features of bronchiolitis,4 were present in the majority of
patients included. Beside the low proportion of prematurity
found in this study, no other risk factors for severe disease,
such as age less than 12 weeks, underlying cardiopulmonary
disease or immunodeficiency, were identified.
Previous studies have reported that breastfeeding
decreases the risk of lower respiratory tract disease (LRTD).
However, the proportion of breastfed infants found in this
study was comparable in both cases and controls. This vari-
able was not shown to increase the risk for developing
pneumonia as a complication in infants hospitalized for
bronchiolitis. A meta-analysis of the relationship of breast-
feeding and hospitalization for LRTD in early infancy that
examined 33 studies showed a protective association
between breastfeeding and the risk of hospitalization for
LRTD.23 In addition, other studies have shown that breast
milk provides immunity and neutralizing factors against RSV,
decreasing hospitalization related to RSV infection and other
lower respiratory tract infections.4 Furthermore, it has been
suggested that breastfed compared with formula-fed infants
responded with higher or equivalent antibody levels to a
series of three doses of conjugate Hib vaccine, leading to
speculation that breastfeeding, or some components of
breast milk, may enhance the active immune response in
the first year of life.24 Conversely, a recent Australian reportdid not show this effect among breastfed infants.25 The
authors suggest that additional studies are needed to deter-
mine the benefits of breast milk on infant Hib immunization
responses.
Since we performed a retrospective analysis of registry
data, we cannot establish cause and effect. However, the
association found is strong and consistent with prior commu-
nity-based studies. Based on these findings, it would be
reasonable to have a low threshold for starting antibiotic
therapy in unvaccinated infants with bronchiolitis who have
physical or radiological features suggesting bacterial pneu-
monia. The antibiotic coverage under these circumstances
should include agents such as third-generation cephalospor-
ins to treat a possible Hib infection. If these results are
validated in further studies, the incorporation of this risk
factor in clinical practice for the prediction of a secondary
bacterial infection as a complication in bronchiolitis could
help to prevent morbidity and mortality from an untreated
bacterial infectious disease in an initially suspected viral
infection. The development of better tools to determine
the microbiological diagnosis of pneumonia is also critical
for additional analysis.
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